We are live on ! Find out more
LSTA icon

Lisata Therapeutics
LSTA

21 hedge funds and large institutions have $2.08M invested in Lisata Therapeutics in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more capital invested

Capital invested by funds: $1.8M → $2.08M (+$280K)

0.89% less ownership

Funds ownership: 9.03% → 8.14% (-0.89%)

9% less funds holding

Funds holding: 23 → 21 (-2)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
21
Holders Change
-2
Holders Change %
-8.7%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$1K
2
Barclays
Barclays
United Kingdom
+$7

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$173K
2
Citadel Advisors
Citadel Advisors
Florida
-$25.1K
3
UBS Group
UBS Group
Switzerland
-$19.7K
4
TRCT
Tower Research Capital (TRC)
New York
-$3.03K
5
IA
IFP Advisors
Florida
-$2K

LSTA Hedge Fund Activity: Q1 2023 in Review

21 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q1 2023, worth a combined $2.08M — up 16% from $1.8M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of LSTA and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was Renaissance Technologies, adding an estimated $1K. The largest seller was Sabby Management, exiting entirely with an estimated $173K sold.

  • 21 institutional investors held Lisata Therapeutics (LSTA) as of Q1 2023, down from 23 in Q4 2022.
  • Funds reported $2.08M of Lisata Therapeutics stock for Q1 2023, up 16% quarter-over-quarter.
  • 2 funds opened new Lisata Therapeutics positions in Q1 2023 and 4 closed out, a net change of -2 holders.
  • The largest Lisata Therapeutics buyer in Q1 2023 was Renaissance Technologies, an estimated $1K added.
  • The largest Lisata Therapeutics seller in Q1 2023 was Sabby Management, an estimated $173K sold.

Based on aggregated 13F filings for Q1 2023.